Comparative effectiveness research could help inform the choice of agent for urate-lowering therapy, the central component of successful gout management. However, if such studies reflect current clinical practice, are they comparing poor management with inadequate management?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Khanna, D. et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthri tis Care Res. (Hoboken) 64, 1431–1446 (2012).
Singh, J. A., Akhras, K. S. & Shiozawa, A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res. Ther. 17, 120 (2015).
Becker, M. A. et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450–2461 (2005).
Becker, M. A. et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res. Ther. 12, R63 (2010).
Schumacher, H. R. Jr. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540–1548 (2008).
Rees, F., Jenkins, W. & Doherty, M. Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study. Ann. Rheum. Dis. 72, 826–830 (2013).
Stamp, L. K. et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum. 63, 412–421 (2011).
Goldfien, R. D. et al. Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open 4, e003627 (2014).
Federal Coordinating Council for Comparative Effectiveness Research. Report to the President and Congress (US Department of Health and Human Services, Washington DC, 2009).
Acknowledgements
N.D. and L.K.S. are supported by the Health Research Council of New Zealand (grant 11/203).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.D. declares she has received consulting fees, speaker fees or grants from Ardea, AstraZeneca, Cymabay, Fonterra, Menarini, Metabolex, Pfizer, Savient, Takeda and Teijin. L.K.S. declares she has received consulting fees from AstraZeneca.
Rights and permissions
About this article
Cite this article
Dalbeth, N., Stamp, L. Why compare the effectiveness of suboptimal gout management?. Nat Rev Rheumatol 11, 506–507 (2015). https://doi.org/10.1038/nrrheum.2015.94
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2015.94
